Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anika Therapeutics Inc (NASDAQ:ANIK)

50.06
Delayed Data
As of Jan 20
 +0.055 / +0.11%
Today’s Change
35.07
Today|||52-Week Range
54.96
+2.24%
Year-to-Date
Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA
Jan 20 / Zacks.com - Paid Partner Content
Jazz Begins Phase III Study for Label Expansion of Defitelio
Jan 18 / Zacks.com - Paid Partner Content
Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy
Jan 20 / Zacks.com - Paid Partner Content
Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval
Jan 18 / Zacks.com - Paid Partner Content
Aduro (ADRO) Inks License Agreement with Stanford University
Jan 20 / Zacks.com - Paid Partner Content
Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit
Jan 18 / Zacks.com - Paid Partner Content
Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter
Jan 19 / Zacks.com - Paid Partner Content
Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017
Jan 17 / Zacks.com - Paid Partner Content
Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico
Jan 19 / Zacks.com - Paid Partner Content
What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
Jan 17 / Zacks.com - Paid Partner Content
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
Jan 19 / Zacks.com - Paid Partner Content
Novartis to Conduct Trial on Obese, Type II Diabetes Patients
Jan 13 / Zacks.com - Paid Partner Content
Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study
Jan 19 / Zacks.com - Paid Partner Content
Pluristem (PSTI) Intermittent Claudication Study Enrolled
Jan 13 / Zacks.com - Paid Partner Content
Allergan's Uterine Fibroids Candidate Positive in Phase III
Jan 18 / Zacks.com - Paid Partner Content
AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
Jan 10 / Zacks.com - Paid Partner Content
Concert Offers Update on Cystic Fibrosis Drug, Stock Down
Jan 18 / Zacks.com - Paid Partner Content
AbbVie's HCV Combo Favorable in Japanese Phase III Study
Jan 10 / Zacks.com - Paid Partner Content
AstraZeneca Offers Update on Immuno-Oncology Program
Jan 18 / Zacks.com - Paid Partner Content
Incyte/Merck to Start More Epacadostat-Keytruda Studies
Jan 10 / Zacks.com - Paid Partner Content
Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo
Jan 18 / Zacks.com - Paid Partner Content
Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
Jan 09 / Zacks.com - Paid Partner Content
Kura Oncology Starts Dosing Patients in Phase II CMML Study
Jan 18 / Zacks.com - Paid Partner Content
Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
Jan 09 / Zacks.com - Paid Partner Content
Benitec Stock Up on Orphan Drug Status for BB-301 in EU
Jan 18 / Zacks.com - Paid Partner Content